Literature DB >> 29787357

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

Dirk De Ruysscher1, Anne-Marie C Dingemans1, John Praag1, Jose Belderbos1, Caroline Tissing-Tan1, Judith Herder1, Tjeerd Haitjema1, Fred Ubbels1, Frank Lagerwaard1, Sherif Y El Sharouni1, Jos A Stigt1, Egbert Smit1, Harm van Tinteren1, Vincent van der Noort1, Harry J M Groen1.   

Abstract

Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery. The primary end point-development of symptomatic brain metastases at 24 months-was defined as one or a combination of key symptoms that suggest brain metastases-signs of increased intracranial pressure, headache, nausea and vomiting, cognitive or affective disturbances, seizures, and focal neurologic symptoms-and magnetic resonance imaging or computed tomography demonstrating the existence of brain metastasis. Adverse effects, survival, quality of life, quality-adjusted survival, and health care costs were secondary end points. Results Between 2009 and 2015, 175 patients were randomly assigned: 87 received PCI and 88 underwent observation only. Median follow-up was 48.5 months (95% CI, 39 to 54 months). Six (7.0%) of 86 patients in the PCI group and 24 (27.2%) of 88 patients in the control group had symptomatic brain metastases ( P = .001). PCI significantly increased the time to develop symptomatic brain metastases (hazard ratio, 0.23; [95% CI, 0.09 to 0.56]; P = .0012). Median time to develop brain metastases was not reached in either arm. Overall survival was not significantly different between both arms. Grade 1 and 2 memory impairment (26 of 86 v seven of 88 patients) and cognitive disturbance (16 of 86 v three of 88 patients) were significantly increased in the PCI arm. Quality of life was only decreased 3 months post-PCI and was similar to the observation arm thereafter. Conclusion PCI significantly decreased the proportion of patients who developed symptomatic brain metastases with an increase of low-grade toxicity.

Entities:  

Mesh:

Year:  2018        PMID: 29787357     DOI: 10.1200/JCO.2017.77.5817

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  22 in total

1.  [Impact of prophylactic cranial irradiation on overall survival of patients with advanced non-small-cell lung cancer].

Authors:  Julia Schmidt; Steffen Appold; Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2019-05       Impact factor: 3.621

2.  Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival.

Authors:  Nuriel Moghavem; Heather A Wakelee; Seema Nagpal
Journal:  Ann Transl Med       Date:  2018-12

3.  The crucial role of predicting brain metastases development in non-small cell lung cancer patients.

Authors:  Alfredo Addeo; Giuseppe Luigi Banna
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Timing, Sites, and Correlates of Lung Cancer Recurrence.

Authors:  Chelsea M Karacz; Jingsheng Yan; Hong Zhu; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-12-20       Impact factor: 4.785

5.  Inter-observer variation of hippocampus delineation in hippocampal avoidance prophylactic cranial irradiation.

Authors:  F Bartel; M van Herk; H Vrenken; F Vandaele; S Sunaert; K de Jaeger; N J Dollekamp; C Carbaat; E Lamers; E M T Dieleman; Y Lievens; D de Ruysscher; S B Schagen; M B de Ruiter; J C de Munck; J Belderbos
Journal:  Clin Transl Oncol       Date:  2018-06-06       Impact factor: 3.405

6.  The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC).

Authors:  I Abuelbeh; O Abu-Shawer; M Abu-Shawer; M Alkderat; M Safi; A Alwazani; A Alkhatib; B Abu-Hussain; M Aladawi; S Ismail; T Altamimi; Taher Abu Hejleh
Journal:  Avicenna J Med       Date:  2022-07-03

Review 7.  Current approaches to the management of brain metastases.

Authors:  John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang
Journal:  Nat Rev Clin Oncol       Date:  2020-02-20       Impact factor: 66.675

8.  Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.

Authors:  Hitoshi Ito; Yukinori Matsuo; Shuji Ohtsu; Takashi Nishimura; Yasuji Terada; Takashi Sakamoto; Takashi Mizowaki
Journal:  Int J Clin Oncol       Date:  2019-10-30       Impact factor: 3.402

9.  Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.

Authors:  Alexander Sun; Chen Hu; Stuart J Wong; Elizabeth Gore; Gregory Videtic; Swati Dutta; Mohan Suntharalingam; Yuhchyau Chen; Laurie E Gaspar; Hak Choy
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

10.  Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment.

Authors:  Lizza E L Hendriks; Deepa S Subramaniam; Anne-Marie C Dingemans
Journal:  Front Oncol       Date:  2018-11-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.